No beneficial effects of pine bark extract on cardiovascular disease risk factors
Abstract
BACKGROUND:
Although modifiable cardiovasculardiseaseriskfactors are common, some patients eschew conventional drug treatments in favor of natural alternatives. Pinebarkextract, a dietary supplement source of antioxidant oligomeric proanthocyanidin complexes, has multiple putative cardiovascular benefits. Studies published to date about the supplement have notable methodological limitations.
METHODS:
We randomized 130 individuals with increased cardiovasculardiseaserisk to take 200 mg of a water-based extract of pinebark (n = 64; Toyo-FVG, Toyo Bio-Pharma, Torrance, California; Shinyaku Co, Ltd, Saga, Japan; also marketed as Flavagenol in Japan) or placebo (n = 66) once per day. Blood pressure, our primary outcome, and other cardiovasculardiseaseriskfactors were measured at baseline and at 6 and 12 weeks. Statistical analyses were conducted using regression models.
RESULTS:
Baseline characteristics did not differ between the study groups. Over the 12-week intervention, the sum of systolic and diastolic blood pressures decreased by 1.0 mm Hg (95% confidence interval, -4.2 to 2.1 mm Hg) in the pinebarkextract-treated group and by 1.9 mm Hg (-5.5 to 1.7 mm Hg) in the placebo group (P = .87). Other outcomes were likewise not significantly different, including body mass index, lipid panel measures, liver transaminase test results, lipoprotein cholesterol particle size, and levels of insulin, lipoprotein(a), fasting glucose, and high-sensitivity C-reactive protein. There were no subgroups for whom intake of pinebarkextract affected cardiovasculardiseaseriskfactors.
CONCLUSIONS:
This pinebarkextract (at a dosage of 200 mg/d) was safe but was not associated with improvement in cardiovasculardiseaseriskfactors. Although variations among participants, dosages, and chemical preparations could contribute to different findings compared with past studies, our results are consistent with a general failure of antioxidants to demonstrate cardiovascular benefits.
Research topics
Related publications
View all publications- The Journal of Clinical Hypertension2017 Jun 19
- Publication
Self-gated fat-suppressed cardiac cine MRI.
Ingle RR, Santos JM, Overall WR, McConnell MV, Hu BS, Nishimura DG.Magn Reson Med. 73(5):1764-74. doi: 10.1002/mrm.25291. Epub 2014 May 7.2015 May 01 - Osnabrugge RL, Arnold SV, Reynolds MR, Magnuson EA, Wang K, Gaudiani VA, Stoler RC, Burdon TA, Kleiman N, Reardon MJ, Adams DH, Popma JJ, Cohen DJ; CoreValve U.S. Trial Investigators.JACC Cardiovasc Interv. 8(2):315-23. doi: 10.1016/j.jcin.2014.08.016.2015 Feb 01
- Ward A, Sarraju A, Chung S, Li J, Harrington R, Heidenreich P, Palaniappan L, Scheinker D, Rodriguez F.NPJ Digit Med. 3:125. doi: 10.1038/s41746-020-00331-1. eCollection 2020.2020 Sep 23
- Wang TY, Xiao L, Alexander KP, Rao SV, Kosiborod MN, Rumsfeld JS, Spertus JA, Peterson ED.Circulation. 118(21):2139-45. doi: 10.1161/CIRCULATIONAHA.108.787143. Epub 2008 Nov 3.2008 Nov 18




